Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target
Benzinga Newsdesk 5 months ago
NewsPrice TargetReiterationAnalyst Ratings
Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Overweight and maintains $220 price target.
Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Overweight and maintains $220 price target.